On day +27, pain in the right upper quadrant, right loin and both legs was reported. Investigations which included an oesophagogastroduodenoscopy, ultrasound and CT scans of the abdomen and magnetic resonance cholangio-pancreatography were unremarkable. Between days +51 and +55 symptoms increased with tiredness, nausea, vomiting, occasional chills, epigastric and right para-umbilical pain which was slow to resolve.
Post-transplant lymphoproliferative disorders (PTLD) refer to lymphoproliferative conditions occurring in immune suppressed post-transplant recipients in whom evidence of Epstein-Barr virus infection can usually be demonstrated.
Milpied et al 1 reported a patient who developed fatal EBV-associated PTLD following a non-myeloablative allogeneic stem cell transplant for ALL. To date, we have performed 30 (19 volunteer unrelated, 11 sibling) reduced intensity transplants using fludarabine (Fludara) 150 mg/m 
Case report
A 53-year-old female (EBV seropositive, CMV seronegative) underwent bone marrow transplant utilising reduced intensity conditioning, for myelodysplastic syndrome (refractory anaemia, with trisomy 8) with unmanipulated bone marrow stem cells from a CMV seronegative, EBV seropositive, fully HLA-matched volunteer unrelated male donor with 3 × 10 6 CD34-positive cells/kg. Conditioning utilised fludarabine (Fludara) 30 mg/m 2 i.v. day −9 to day −5, busulphan 4 mg/kg p.o. day −3 to day −2 and CAMPATH-1H* 20 mg i.v. day −5 to day −1. GVHD prophylaxis comprised short-course methotrexate 10 mg/m 2 i.v. on days +1, +3 and +6 together with cyclosporine, titrated to plasma trough levels of approximately 150-200 ng/l. Aciclovir 200 mg three times a day was given as antiviral prophylaxis. The immediate post-transplant course was unremarkable except for mild palmar/plantar GVHD which did not require specific therapy.
On day +27, pain in the right upper quadrant, right loin and both legs was reported. Investigations which included an oesophagogastroduodenoscopy, ultrasound and CT scans of the abdomen and magnetic resonance cholangio-pancreatography were unremarkable. Between days +51 and +55 symptoms increased with tiredness, nausea, vomiting, occasional chills, epigastric and right para-umbilical pain which was slow to resolve.
A repeat OGD, ERCP and gastric biopsy on day +69, was consistent with 'chronic gastritis'. A presumptive diagnosis of GVHD was made and further immune suppression was commenced on day +70 with a reducing dose of prednisolone 40 mg/day, tapered over 4 weeks. Cyclosporine and aciclovir prophylaxis was continued. This resulted in rapid resolution of all symptoms.
She remained relatively well till day +128, when bilateral paraesthesia and pain affecting both lower limbs was experienced. Bone marrow examination showed full donor engraftment with a male karyotype, confirmed by vWF variable number tandem repeats (VNTR) analysis.
Increasing right upper quadrant pain, fever, confusion and left-sided neurological symptoms led to readmission on day +191. CT scans of the head revealed two hypodense lesions thought to be consistent with infarcts. Ultrasound of the abdomen was reported as 'normal' except for a small amount of ascitic fluid.
On day +195, a CT scan of the abdomen performed because of increasing right hypochondrial and iliac fossa tenderness and guarding revealed free peritoneal gas. At laparotomy, a perforated proximal descending colon and a necrotic caecum with a right retroperitoneal abscess was found. A total colectomy was performed. Rapid deterioration in her clinical condition and death occurred soon after. Permission for a post-mortem was declined.
Morphologically, the caecal and colonic mucosa showed several deep fungating necrotic ulcers extending to the resection margins, with multiple full thickness perforations. A dense transmural infiltrate of large tumour cells displaying plasmacytoid, immunoblastic and centroblastic features, was present, invading nerves and vasculature. Large lymph nodes showed marked necrosis and complete replacement by tumour cells. Immunohistochemical staining with anti-CD20 and EBER (EBV-encoded small RNAs) was diffusely positive (Figure 1 ).
Fluorescence in situ hybridisation (FISH) was carried out on formalin-fixed, paraffin-embedded lymph node tissue 
Discussion
Reduced intensity haemopoietic stem cell transplants harness the T cell-mediated graft-versus-malignancy effect and have been shown to be a viable alternative to standard bone marrow transplantation with an improved short-term transplant-related mortality (TRM) and morbidity. [3] [4] [5] [6] It is dependent upon profound short-term immunosuppression with fludarabine or low-dose TBI and an anti-T cell antibody, together with a short course of cyclosporine, with or without mycophenolate mofetil. The 'non-myeloablative' properties of conditioning result in various degrees of mixed donor-recipient chimerism which may be reversed with incremental infusions of donor T cells. To date, there has been one previous report of an EBV-positive PTLD occurring post-reduced intensity HSCT utilising fludarabine, busulphan and ATG. 1 In the presence of mixed donorrecipient chimerism, PTLD could theoretically be derived from either host or recipient B cells. In this instance, we confirmed the donor origin of the malignant tissue, EBER and anti-CD20 positivity (Figure 1) .
Retrospectively, the initial symptoms at day +27 may have represented protean manifestations of PTLD despite unrevealing imaging investigations. Serial quantification of EBV viral load in this case may have assisted in making an earlier diagnosis. This presumably assumed a chronic progressive course, possibly modified by steroid therapy commenced on day +70 before entering a rapidly progressive terminal phase at about day +190.
PTLD is a well recognised complication of transplantation. In conventional allogeneic bone marrow transplantation, approximately 1.8% developed PTLD at a median of 90.5 days (range 34-282) post BMT. 7 Of 18 014 patients in 235 centres world-wide, PTLD developed in 78 recipients (0.43%), with 64 (82%) occurring less than 1 year after transplantation. 8 The highest incidence of 1.2% per year occurred 1 to 5 months post transplant, with major risk factors being HLA disparity, T cell depletion and the use of ATG or anti-CD3 antibodies. CAMPATH (anti-CD52) which removed both B and T cells was associated with less risk than methods which selectively depleted T cells. 8, 9 The in vivo timing of CAMPATH in our schedule, designed to minimise graft rejection and GVHD, would deplete both donor and recipient CD52-positive cells.
Cellular immunity against EBV does not appear to be reconstituted until at least 6 months post conventional BMT. 10 Following the use of CAMPATH-1H, Steven and colleagues 11 demonstrated that the median time to first EBV-specific T cell response was longer in reduced intensity HSCT patients who had received fludarabine and CAMPATH-1H (8 months) than recipients of CAMPATH-1H in conventional HSCT (4 months).
The period of highest risk for PTLD corresponds to the period of absent or impaired T cell surveillance. Theoretically, therefore, the risk of developing PTLD in recipients of reduced intensity HSCT is greater than in conventional HSCT. With growing accumulated experience in reduced intensity HSCT, the true risk of PTLD will become clearer. As it remains a complication associated with a high mortality, we suggest a schedule of monitoring of EBV viral load in post-transplant recipients, with the institution of preemptive treatment using donor leucocytes, 12 EBV-specific CTLs, 13 GM-CSF, 14 or anti-CD20, 15, 16 in those at risk, together with titration of immunosuppression, in an effort to avoid the high mortality associated with PTLD and conventional cytotoxic chemotherapy. Assessment of the tempo of EBV-specific T cell reconstitution will help in our further understanding of the risks of PTLD. Whilst the role of the former is being examined, a high index of suspicion should exist, particularly for the protean early manifestations.
